Testing LY4226695 in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early-phase interventional trial examines the safety, tolerability, and pharmacokinetics of LY4226695 compared with placebo in healthy participants. The study includes multiple parts with short stays in a Clinical Research Unit to monitor effects and collect blood samples over about 64 to 92 days. Participants undergo periodic inpatient visits to assess how the drug behaves in the body and what side effects may occur. Parts B and C include specific geographic eligibility for Chinese and Japanese cohorts, respectively.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have a screening body mass index (BMI) in the range of 18.5 to 35 kilograms per square meter (kg/m²), inclusive, with no significant weight gain or loss in the past 3 months prior to screening.
* Individuals assigned male at birth must agree to adhere to contraception restrictions and individuals assigned female at birth must not be of childbearing potential.
* Part B Chinese participants:

  * To qualify as a Chinese participant for the purpose of this study, all the participants' biological grandparents must be Chinese and born in China.
* Part C Japanese participants:

  * To qualify as a Japanese participant for the purpose of this study, all the participants' biological grandparents must be Japanese and born in Japan.

Exclusion Criteria:

* Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders.
* Have known or ongoing psychiatric disorders.
* Have a history of deep vein thrombosis of the leg or repeated episodes of deep leg vein thrombosis in first-degree relatives (parents, siblings, or children).
* Have a history of fracture within 6 months prior to screening.
* Have a history of fainting.
* Regularly use known drugs of abuse or with positive drug results.
* Have alcohol intake that exceeds recommended average weekly alcohol consumption limits per local regulation.

Where it's running

• Lilly Centre for Clinical Pharmacology
  Singapore, Singapore Recruiting
• CenExel ACT
  Anaheim, California, United States Not yet recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 1-317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Abemaciclib in healthy adults: comparing tablet and granule forms to see how they enter the bloodstream

  This study tests different oral forms of abemaciclib in healthy volunteers to see how much and how fast the drug gets into the blood and what side effects occur.

  Recruiting Phase 1 Eli Lilly and Company · Singapore · NCT07818967

• Weekly tirzepatide vs placebo for pediatric obesity (6 to <12 years)

  This study tests whether weekly tirzepatide can help children aged 6 to under 12 with obesity, in addition to healthy lifestyle guidance.

  Recruiting at 2 sites Phase 3 Eli Lilly and Company · Tucson, Arizona and 81 other locations · NCT07817875

• Testing LY4329090 in adults with overweight or obesity who are otherwise healthy

  This study tests how LY4329090 works in adults with overweight or obesity who are otherwise healthy to see if it is tolerated and what side effects might occur.

  Recruiting at 2 sites Phase 1 Eli Lilly and Company · Daytona Beach, Florida and 2 other locations · NCT07808073

• Eloralintide and birth-control pill study in women with overweight or obesity

  This study tests whether eloralintide affects how oral contraceptives work in women with overweight or obesity.

  Recruiting at 2 sites Phase 1 Eli Lilly and Company · Daytona Beach, Florida and 1 other locations · NCT07808060

• Tirzepatide for type 1 diabetes patients who are overweight or obese

  This study tests whether tirzepatide can affect stomach emptying in adults with type 1 diabetes and overweight or obesity.

  Recruiting Phase 1 Eli Lilly and Company · Miami, Florida · NCT07803744

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.